1. Home
  2. PXMD

PXMD

PaxMedica Inc.

Logo PaxMedica Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-17-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Founded: N/A Country:
United States
United States
Employees: N/A City: TARRYTOWN
Market Cap: 6.2M IPO Year: 2022
Target Price: $3.00 AVG Volume (30 days): 2.4M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -11.00 EPS Growth: N/A
52 Week Low/High: $0.37 - $38.93 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: